Alfuzosin

From Wikipedia, the free encyclopedia

Alfuzosin
Systematic (IUPAC) name
N-[3-[(4-amino-6,7-dimethoxy-quinazolin-2-yl)- methyl-amino]propyl] tetrahydrofuran- 2-carboxamide
Identifiers
CAS number 81403-80-7
ATC code G04CA01
PubChem 2092
DrugBank APRD00490
Chemical data
Formula C19H27N5O4 
Mol. mass 389.449 g/mol
Pharmacokinetic data
Bioavailability 49%
Protein binding 82%-90%
Metabolism Hepatic (CYP3A4-mediated)
Half life 10 hours
Excretion Fecal (69%) and renal (24%)
Therapeutic considerations
Pregnancy cat.

B2(AU) B(US)

Legal status

POM(UK) -only(US)

Routes Oral

Alfuzosin (INN, provided as the hydrochloride salt) is an alpha-adrenergic blocker used to treat benign prostatic hyperplasia (BPH). It works by relaxing the muscles in the prostate and bladder neck, making it easier to urinate.

Alfuzosin is marketed in the United States by Sanofi Aventis under the brand name Uroxatral and elsewhere under the tradename Xatral. Alfuzosin was approved by the FDA for treatment of BPH in June 2003.

[edit] Side effects

The most common side effects are dizziness (due to postural hypotension), upper respiratory tract infection, headache, and fatigue.

[edit] Contraindications

Alfuzosin should be used with caution in patients with severe renal insufficiency, and should not be prescribed to patients with a known history of QT prolongation or to patients who are taking medications known to prolong the QT interval.


[edit] External links


Languages